perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

TFF1 – a new Biomarker in Liquid Biopsies of Retinoblastoma under Therapy

Maike Anna Busch1*#, André Haase1#, Emily Alefeld1, Eva Biewald2, Leyla Jabbarli2 and Nicole Dünker1

- ¹ Institute of Anatomy II, Department of Neuroanatomy, Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University of Duisburg-Essen, Medical Faculty, Essen, Germany; andre.haase@uk-essen.de (AH); emily.alefeld@stud.uni-due.de (EA); nicole.duenker@uk-essen.de (ND)
- ² Department of Ophthalmology, Children's Hospital, University of Duisburg-Essen, Essen, Germany; eva.biewald@uk-essen.de (EB); leyla.jabbarli@uk-essen.de (LJ)
- Correspondence: maike.busch@uk-essen.de; Tel.: +49 201 / 723-84434
- # shared first authorship

Simple Summary:

Effective management of retinoblastoma (RB), a common childhood eye cancer, requires 13 accurate diagnosis and monitoring during therapy. In this study the liquid biopsy marker 14 potential of the secreted trefoil family factor peptide 1 (TFF1), described as a biomarker of 15 a more advanced RB subtype, was explored. TFF1 expression levels were investigated in 16 aqueous humor (AH) of RB patients after enucleation and in RB patients undergoing in-17 travitreal chemotherapy and compared with TFF1 expression levels in RB patients' blood 18 serum. AH showed consistent TFF1 levels in a subgroup of RB patients, remarkably de-19 creasing post-therapy in responsive patients. Blood serum of RB patients only displayed 20 low to non-detectable and therapy-independent TFF1 levels. The study suggests TFF1 ex-21 pression in AH as a reliable biomarker, aiding RB diagnosis and treatment assessment 22 and highlights it's potential for non-invasive RB therapy monitoring. 23

Abstract:

Effective management of retinoblastoma (RB), the most prevalent childhood eye cancer, 25 depends on reliable monitoring and diagnosis. A promising candidate in this context is 26 the secreted trefoil family factor peptide 1 (TFF1), recently discovered as a promising new 27 biomarker in patients with a more advanced subtype of retinoblastoma. The present study 28 investigated TFF1 expression within aqueous humor (AH) of enucleated eyes and com-29 pared TFF1 levels in AH and corresponding blood serum samples from RB patients un-30 dergoing intravitreal chemotherapy (IVC). TFF1 was consistently detectable in AH, con-31 firming its potential as a biomarker. Crucially, our data confirmed that TFF1 secreting 32 cells within the tumor mass originate from RB tumor cells, not from surrounding stromal 33 cells. IVC therapy responsive patients exhibited remarkably reduced TFF1 levels post-34 therapy. By contrast, RB patients' blood serum displayed low to undetectable levels of 35 TFF1 even after sample concentration and no therapy-dependent changes were observed. 36 Our findings suggest that compared to blood serum AH represents the more reliable 37 source for TFF1 if used for liquid biopsy RB marker analysis in RB patients. Thus, analysis 38 of TFF1 in AH of RB patients potentially provides a minimal invasive tool for monitoring 39 RB therapy efficacy, suggesting its importance for effective treatment regimens. 40



1

2

3

4

5

6

7

8 9

10

11

12

24

 Keywords: Retinoblastoma, TFF1, aqueous humor, liquid biopsy, therapy monitoring
 42

 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
 43



perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

1. Introduction

Retinoblastoma (RB), the most common pediatric ocular malignancy, arises from the un-46 controlled proliferation of developing retinal cells [1,2] and is characterized by the loss or 47 mutation of both copies of the RB1 gene, which regulates the cell cycle and inhibits tumor-48 igenesis [3–6]. The disease manifests predominantly in children under five years of age, 49 affecting both eyes in approximately 40% of all cases [5]. If left untreated, retinoblastoma 50 can lead to severe visual impairment and, in most unfavorable cases, metastatic spread 51 through the optic nerve into the central nervous system [1,7,8]. Traditional therapeutic 52 methods for RB involve invasive procedures such as enucleation of the affected eye or 53 systemic chemotherapy, which leads to lifetime visual limitations posing various risks to 54 the patient [9–11]. Intravitreal chemotherapy (IVC) has emerged as a highly effective ther-55 apeutic modality for retinoblastoma, particularly for intraocular tumors [12–18], involv-56 ing the direct injection of chemotherapeutic agents into the vitreous cavity of the affected 57 eye, allowing for targeted treatment and reduced systemic toxicity. While IVC has shown 58 promising results in managing RB, therapy monitoring remains crucial for the assessment 59 of treatment efficacy and early detection of potential recurrence. Tissue biopsy is generally 60 considered contraindicated for RB, as it is believed to promote extraocular spread [19]. 61 Nevertheless, in some cases tissue biopsy is relevant as it allows for a reliable confirmation 62 of RB diagnosis and the assessment of the RB1 mutational status for prognostic counseling 63 [20]. Despite the use of optical coherence tomography and B-scan ultrasonography, sev-64 eral differential diagnoses such as Coats disease, persistent fetal vasculature, retinopathy 65 of prematurity, coloboma, and toxocariasis may be misdiagnosed as RB [19], eventually 66 resulting in enucleation of infants for unequivocal diagnostic purposes [21]. 67

Liquid biopsy offers a non-invasive alternative by detecting tumor-derived components, 68 such as circulating tumor cells (CTCs), cell-free DNA (cfDNA), exosomes, microRNAs, 69 and other secreted factors, in easily accessible body fluids like blood or aqueous humor 70 (AH) [22–24]. Aqueous humor paracentesis is a straightforward and safe procedure com-71 monly conducted under general anesthesia in conjunction with eye examinations in RB 72 infants, which can also be combined with intravitreal administration of chemotherapy 73 [24]. In recent decades, the identification of specific biomarkers - also detectable in in liq-74 uid biopsies - revolutionized cancer research and clinical practice [25-27]. Biomarkers, as 75 measurable indicators of biological processes or disease states, play a crucial role in early 76 detection, diagnosis, prognosis, and the development of targeted therapies for various 77 malignancies [28,29] including RB. This technique not only presents an opportunity for 78 early detection but also allows for real-time monitoring of disease progression and re-79 sponse to treatment [30,31]. 80

Among the potential biomarkers for RB, trefoil factor family peptide 1 (TFF1) has emerged 81 as an intriguing candidate with promising implications for cancer management [1,22,32]. 82 TFF1, a member of the trefoil factor family peptides, plays crucial roles in maintaining 83 mucosal integrity and promoting epithelial repair in various tissues [33-36]. Recent stud-84 ies suggested a potential link between TFF1 and tumorigenesis, e.g clinico-pathological 85 features, highlighting the diagnostic and prognostic value of TFF1 as a cancer biomarker. 86 Previous studies by our group showed that RB cells lines and RB tumors express variable 87 levels of TFF1 [46–48], while it is not expressed in the healthy human retina. Most recently 88 we could demonstrate that TFF1 is also detectable in the aqueous humor of RB patients 89 [23], rendering it a highly promising candidate as a RB biomarker in liquid biopsies. As a 90 secreted, extracellular protein, TFF1 can be detected in body fluids [23,40,41], circumvent-91 ing the need for invasive procedures. Besides a prospective biomarker like TFF1 poten-92 tially aids at early cancer detection, monitoring treatment response, and assessing disease 93 progression, thereby improving patient outcomes. 94

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

In the study presented, we will shed light onto the potential of TFF1 as a non-invasive 95 diagnostic and prognostic marker in RB liquid biopsies. TFF1 levels in RB patients' aque-96 ous humor and blood may not only enable early cancer detection, but also serve as a val-97 uable indicator for monitoring therapy efficacy. Changes in TFF1 expression or release 98 during the course of RB treatment might provide insights into treatment response and 99 help to identify patients who may require additional interventions. Integrating TFF1 as-100 sessment into liquid biopsy protocols for RB patients could enhance therapeutic decision-101 making and improve long-term outcomes. As such, a comprehensive understanding of 102 TFF1 as a cancer biomarker holds promise in shaping the future of RB diagnostics and 103 personalized treatment approaches, ultimately contributing to improved clinical out-104 comes and quality of life for affected children. 105

106

107

132

2.1. Human retinoblastoma tumor, aqueous humor and blood samples

Human retinoblastoma (RB) primary tumor material, aqueous humor samples from enu-
cleations of 8 patients as well as aqueous humor and blood serum samples from 7 RB
patients under therapy and 6 healthy individuals (control group) were used for TFF1 ex-
pression studies. The Ethics Committee of the Medical Faculty of the University of Duis-
burg-Essen approved the use of retinoblastoma samples (approval # 14-5836-BO) for re-
search conducted in the course of the study presented and written informed consent has
been obtained from patients' relatives or parents.108

Primary tumor material and aqueous humor samples of eight patients were harvested 115 immediately after enucleation (T27, T31, T32, T34, T36, T38, T40 and T41). Aqueous humor 116 was aspirated via an anterior chamber puncture using a 30 G needle. In the next step, the 117 actual tumor was removed from the globe via scleral fenestration. Aqueous humor and 118 blood serum samples of seven patients were harvested under anesthesia prior to IVC 119 treatment with melphalan. Subsequently, blood was centrifuged at 2,500 G for 15 min at 120 18°C. Separated serum fraction aliquots were stored at minus 80°C until further use. Be-121 sides, blood was drawn from six healthy individuals as a control group. Aqueous humor 122 were stored at minus 80°C until use or further processing (see below), and tumor tissue 123 samples were cultured as described below. 124

This study includes a case series of eight untreated eyes from individual children diag-125nosed with intraocular retinoblastoma (out of 2022) and seven treated eyes from individ-126ual children diagnosed with intraocular retinoblastoma between 2022 and 2023. Diagnosis127of the untreated eyes was confirmed by a specialized pathologist after enucleation. The128data collected included patient's age at diagnosis, gender, laterality, ICRB stage (Interna-129tional Classification of Retinoblastoma), RB1 mutation status, tumor volume/size, optic130nerve and choroid invasion.131

2.2. Primary RB Cell Culture

The primary RB tumor material was initially cut up to small pieces with a sterile scalpel 133 and subsequently washed three times in PBS with a centrifugation step in between (800 134 rpm for 2 minutes). After the last washing step the tumor material was cultivated in Dul-135 becco's modified Eagle's medium (DMEM; PAN-Biotech, Aidenbach, Germany) with 15% 136 fetal calf serum (FCS; PAN-Biotech, Aidenbach, Germany), 100 U penicillin/ml and 100 137 µg streptomycin/ml (Invitrogen, Darmstadt, Germany), 4 mM L-glutamine (Sigma-Al-138 drich, München, Germany), 50 µM ß-mercaptoethanol (Carl-Roth, Karlsruhe, Germany) 139 and 10 µg insulin/ml (Sigma-Aldrich, München, Germany) at 37°C, 10% CO2 and 95% 140humidity as described previously (Busch et al. 2015). The cells separated in culture into 141 suspension (RB tumor cells) and adherent populations (RB derived stroma cells) and were 142

subsequently cultured separately. Supernatants from both subcultures were harvested 143 and residual cells were removed by centrifugation. Cell culture supernatants were kept at 144 -20° C until usage. 145

2.3. Blood serum concentration and TFF1 ELISA analysis

Right before use, blood serum samples were concentrated up to 5-fold using protein con-147 centrator column (3 kDa MWCO, Thermo Fischer Scientific, MA, USA) following the man-148 ufacturer's instructions. One hundred microliters aqueous humor samples and concen-149 trated blood serum from RB patients were analyzed using a human TFF1 ELISA kit 150 (ab213833, abcam, Cambridge, UK) according to the manufacturer's protocol. The stand-151 ard curve included in the kit was used to determine the concentration of the samples an-152 alyzed. 153



Figure 1. Workflow diagram of the TFF1 ELISA analysis. Created with BioRender.com. 155

2.4. Immunhistochemistry and immunfluorescence stainings

TFF1 immunostaining was performed with the Vectastin Elite ABC kit (Vector Laborato-157 ries, Burlingame, CA, USA) as previously described by our group [48]. The following an-158 tibody were used: TFF1 (1:200, abcam, Cambridge, UK, # ab92377). Images were acquired 159 using an Aperio ScanScope AT2 (Leica, Wetzlar, Germany) slide scanner. 160

For immunofluorescence staining of TFF1, 1 x 10⁵ cells were seeded on poly-D-lysine 161 (Sigma, Hamburg, Germany) coated coverslips and stained as previously described by 162 our group [23]. Pictures were taken with a NIKON Eclipse E600 microscope equipped 163 with a digital camera and NIKON Eclipse net software. 164

2.5. Statistical analysis

Statistical analyses were performed using GraphPad Prism 9. Results were analyzed by a 166 Student's t-test and considered significantly different if *p < 0.05, **p < 0.01, ***p < 0.001167 or ****p<0.0001. 168

169

165

154

156

- 170
- 171

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

3. Results

3.1. Soluble TFF1 in aqueous humor of RB patients is secreted by RB tumor cells

In a most recent study we discovered TFF1 expression in a specific subgroup of 176 retinoblastoma (RB) tumors with advanced stages, and found this soluble peptide to be 177 secreted into the aqueous humor of RB patients [23]. To expand our investigation to a 178 larger cohort of RB patients, we analyzed aqueous humor (AH) samples from eight 179 additional RB patients after enucleation. Table 1 summarizes the clinical and pathological 180 characteristics of the RB patients analyzed. 181

Table 1. Clinical and pathological characteristics of RB patients stratified by TFF1 183 expression in aqueous humor. NA: not available, n: number in each group, N: total number, ICRB: International Classification of Retinoblastoma 185

	TFF1 expressed n (%)	TFF1 not expressed n (%)	Ν
Patients	7 (87.5)	1 (12.5)	8
Sex			
female	2 (28.6)	0 (0)	2
m	5 (71.4)	1 (100)	6
ICRB stage			
D	1 (14.3)	0 (0)	1
E	4 (57.1)	1 (100)	5
NA	2 (28.6)	0 (0)	2
Laterality			
unilateral	7 (100)	1 (100)	8
bilateral	0 (0)	0 (0)	0
Age at diagnosis			
<18 month	0 (0)	1 (100)	1
18-36 month	6 (85.7)	0 (0)	6
>36 month	1 (14.3)	0 (0)	1
Tumor volume			
<1 cm ³	1 (14.3)	0 (0)	1
2-3 cm ³	2 (28.6)	0 (0)	2
>3 cm ³	4 (57.1)	1 (100)	5
Optic nerve invasion			
none	5 (71.4)	1 (100)	6
p-laminar	2 (28.6)	0 (0)	2
post-laminar	0 (0)	0 (0)	0
Choroid invasion			
none	7 (100)	1 (100)	8
invasion	0 (0)	0 (0)	0

Using a specific, highly sensitive TFF1 ELISA (Figure 2a) allowed us to confirm that RB 187 tumor cells secrete soluble TFF1 into the aqueous humor of RB patients' eyes. 188

186

182

172 173

174 175

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Six out of eight tumors analyzed secreted high concentrations of TFF1 (ranging between 189 1000 and 4500 pg/ml; labeled as T27, T36, T31, T40, and T41) into the AH. Additionally, 190 we found one tumor (T38) with moderate levels of TFF1 secretion. Only one (T32) out of 191 eight tumors did not secrete any detectable TFF1 into the AH. 192

In order to compare the expression pattern of TFF1 in AH with its expression in original 193 RB tumor specimens, we performed immunhistochemical staining for TFF1 on paraffin 194 sections of enucleated patients eyes baring the investigated tumors. Remarkably, all 195 tumors displaying detectable TFF1 in the AH samples also stained positive for TFF1 in the 196 primary tumor sections (Figure 2b). 197

These results further support our previous findings and indicate that detection of TFF1 in 198 RB patients' AH represents a reliable marker for the presence of TFF1-secreting RB tumor 199 cell. This finding holds promise for potential applications in RB patient monitoring and 200 treatment strategies. 201



203

Figure 2. TFF1 expression analyses in aqueous humor samples and corresponding 204 histological analysis of RB tumors in enucleated eyes of RB patients. (a) TFF1 ELISA 205 analysis of 8 aqueous humor samples of RB patients, displaying six tumors highly 206 expressing TFF1 (>400 pg/ml), one patient's tumor with average TFF1 expression (30-400 207 pg/ml) and one patient without TFF1 expression (0-30 pg/ml) in the aqueous humor. 208 Vertical dotted lines indicate three TFF1 expression levels. (b) TFF1 expression in the 209 corresponding primary tumors is shown exemplarily for T34 (high TFF1 expression in 210 AH) and T32 (no TFF1 expression in AH). Immunohistochemistry was revealed using 211 diaminobenzidine detection (brown signal) and hematoxylin counterstaining (blue nuclei 212 staining). Scale bars: 300µm. 213

To investigate whether TFF1 is exclusively secreted by RB tumor cells and not by 215 surrounding stromal tissue, we compared supernatants of a primary stromal cell culture 216 and a primary RB tumor cell culture, both derived from enucleations of RB tumor baring 217 patient eyes. The primary stromal cells did not carry the RB1 mutation present in the 218 primary RB tumor cells, indicating their non-tumor identity. As expected, ELISA analysis 219 revealed no detectable TFF1 secretion in the supernatant of the stromal cell culture (data 220 not shown). 221

To further validate these results, we conducted immunofluorescence staining to assess the 222 cellular expression of TFF1. The intracellular TFF1 expression pattern closely correlated 223 with the TFF1 secretion status observed in the RB tumor cells and RB tumor-derived 224 stromal cells. Specifically, primary RB tumor cells exhibited high levels of TFF1 expression 225

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

(Figure 3a), while the corresponding RB derived stromal cells showed no detectable TFF1 226 expression (Figure 3b). 227

In summary, our previous findings [23] were confirmed by analyzing AH samples from 228 enucleated RB eyes via TFF1 ELISA. Additionally, we demonstrated that the cells 229 secreting TFF1 originate from tumorigenic cells and not from the stromal compartment of 230 the RB tumor mass. This discovery highlights TFF1 as a potential marker for minimal 231 invasive therapy monitoring via AH aspiration. 232



Figure 3. Immunofluorescence TFF1 staining of primary RB cell cultures. (a) Pictures of a primary cell culture of RB tumor cells and (b) corresponding RB tumor derived stromal cells in DAPI (blue), TFF1 (red) and merged DAPI/TFF1 immunofluorescenc staining (200x). RB tumor cells showed a high expression of TFF1 in contrast to the corresponding stromal cells, displaying no TFF1 expression. Scale bars: 50 µm

3.2. Analysis of soluble TFF1 secretion in AH and blood of RB patients under therapy

Monitoring and diagnosing RB is crucial to distinguish it from other diseases, evaluate 243 treatment effectiveness, and identify potential recurrences. However, as RB tumor 244 biopsies are not feasible, there is an urgent need for reliable biomarker to determine 245 diagnosis and treatment success in non-enucleated RB tumors. 246

To investigate if secreted TFF1 expression changes in liquid biopsies during therapy, we247examined a series of AH and corresponding blood samples from 7 RB patients using TFF1248ELISA. Liquid biopsies (AH and blood) were collected before the indicated intravitreal249chemotherapy (IVC) treatment cycles with melphalan. We found that 3 out of the 7 RB250patients (T28, T33, and T44) expressed soluble, secreted TFF1 in their AH (Figure 4a).251

The first AH sample of the tumor with the highest AH TFF1 concentration (T44) observed252in our study was received from the clinics after two IVC cycles with melphalan. Thus, no253information about the initial TFF1 concentration in the AH prior to therapy is available.254We nevertheless included this specimen in our monitoring due to a remarkable decrease255in TFF1 levels under therapy, which dropped to zero after only one additional IVC cycle.256

Similarly, the tumor with the second-highest AH TFF1 concentration (T33) displayed a 258 reduction to zero after only two therapy cycles. Interestingly, treatment outcome seems to 259 correlate with the reduction of TFF1 expression in the AH in all RB tumors. Both tumors 260 with TFF1 expression dropping to zero during IVC therapy responded well to treatment 261

235 236

233

238 239

237

- 240
- 241 242

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

and showed positive outcomes as revealed by fundoscopy (Figure 4b) displaying a 262 regression and calcification of the vitreous seeding. On the other hand, patient T28 263 exhibiting a constant TFF1 expression in the AH during therapy (Figure 4a, IVC cycle 1-264 3), exhibited a relapse after five month (Figure 4b), while still expressing high TFF1 levels 265 in the AH (Figure 4a, IVC cycle 4). 266

These findings suggest that monitoring soluble TFF1 levels in the aqueous humor of RB 267 patients under therapy could serve as a potential biomarker to assess treatment efficacy 268 and predict therapeutic outcomes in non-enucleated RB tumors. This could significantly 269 improve RB therapy management and patient care. 270



Figure 4. TFF1 expression analyses in aqueous humor samples of RB patients during 273 therapy. (a) TFF1 ELISA analysis of three aqueous humor samples of RB patients taken 274 prior to the indicated intravitreal chemotherapy (IVC) cycle with melphalan. All three 275 patients initially expressed TFF1 (30-400 pg/ml) in the aqueous humor. Values below the 276 vertical dotted line represent no TFF1 expression (0-30 pg/ml). (b) Fundoscopy pictures of of the three RB patients prior (initial) and after IVC with melphalan. For patient T28 a picture of the relapse after 5 month is provided.

Additionally, we examined corresponding blood serum samples from the 7 RB patients, 281 who underwent therapy and compared them to three control samples from non-RB 282 children and three healthy adolescents. Detecting TFF1 in blood serum required prior 283 concentration of the samples (as described in the materials and methods section) and even 284 after concentration, only fairly low TFF1 levels (~10 pg/ml) were detectable. Comparing 285 TFF1 levels among individuals of the control groups we found young non-RB baring 286 children under the age of six to display no detectable TFF1 expression compared to the 287 healthy adolescent group (>14 years), expressing low levels of about 10 pg/ml TFF1 288 (Figure 5). 289

Among the seven RB serum samples investigated, we detected low concentrations of TFF1 290 in three samples (< 12 pg/ml). However, in these patients, no TFF1 was detectable in the 291 AH. Notably, one of the RB patients displaying detectable TFF1 expression in the blood 292 was of higher age (Figure 5b), suggesting that serum expression might be related to the 293 patient's age. 294

In one RB patient, TFF1 expression was neither detectable in blood nor in AH (T26, Table 295 2). Furthermore, patient T28, whose TFF1 expression in AH remained unchanged during 296 therapy, showed no detectable TFF1 expression in blood serum (Table 2). For patients T33 297 and T44, whose AH TFF1 expression dropped to zero under therapy, TFF1 expression was 298

272

271

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

only randomly found in individual blood serum samples without a distinct expression 299 pattern (Table 2). 300

Overall, no therapy-dependent changes in TFF1 expression were detectable in blood301serum of any of the RB patients studied (Table 2), rendering blood serum unsuitable for302TFF1 biomarker analyses. These findings indicate that AH remains the reliable source for303monitoring TFF1 levels and assessing treatment responses in RB patients.304



Figure 5. TFF1 expression analyses in blood serum and aqueous humor samples. (a)306Comparison of TFF1 blood serum levels in control groups of non-RB children under the
age of 6 years with healthy individuals over 14 years. (b) Comparison of TFF1 blood serum
levels (serum) with TFF1 expression in aqueous humor (AH) of patient T24. Values are
means of three samples \pm SEM. ****p<0.0001 statistical differences compared to the control
group calculated by students t-test.306

Table 2 summarizes clinical and pathological characteristics as well as TFF1 expression313levels found in AH and blood serum samples of the 7 RB patients analyzed during314therapy.315

316

312

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

317

Table 2. Clinical and pathological characteristics of RB patients under IVC therapy with318melphalan stratified by TFF1 expression in liquid biopsies (aqueous humor and blood319serum). Red and blue labeling indicates the respective tumor analyzed in case of320bilaterality321

Case ¹	Sex	Age at diagnosis (month)	Lateraliy	ICRB stage	Tumor size (mm)	Enucleation	Optic nerve invasion (MRI)	Choroid invasion (MRI)	<i>RB1</i> mutation	Sample number	AH TFF1 (pg/ml)	Serum TFF1 (pg/ml)	
		t: 18-36		ri• B	ri• 1 5					1	0	9.73	
T24 [#]	m	r >36	b	le E	le: >10	le: PE	no	no	yes	2	0	9.97	
		1.200		IC. L	IC. 7 10					3	0	11.12	
										1	0	11.55	
										2	0	0	
T25	f	18-36	11	П	87	no	no	VAC	no	3	0	10.6	
125	1	10-50	u	D	0.7	110	110	yes	110	4	0	0	
										5	0	0	
										6	0	0	
					0					1	0	0	
T26	m	<18	b	D	9 (both)	le: SE	no		yes	2	0	0	
					(sour)	1e. 5E		ie. yes		3	0	0	
	f	t: 18-36 f r: >36 <i>r2: >36</i>				ri: no	ri: no	ri: no		1	118.98	0	
mea#			h	Б	ri: 12					2	124.37	0	
T28#			1. 200	D	Е	le: 20	le: PE	le: yes	le: yes	yes	3	95.9	0
										4	119.41	0	
										1	180.21	10.65	
										2	54.28	9.23	
										3	0	0	
										4	0	0	
										5	0	0	
T33	m	18-36	u	D	n/a	no	n/a	n/a	n/a	6	0	9.33	
										7	0	0	
											8	0	0
										9	0	9.83	
										10	0	10.14	
										11	0	0	
	f	18-36		ri: E le: D	ri: 22 le: 7	ri: SE le: no	ri: yes le: no	ri: yes le: no		1	0	9.93	
T39			18-36 b						yes	2	0	0	
										3	0	9.98	
		>36	>36								*	340.58	10.57
T44	m			u	С	8	no	no	no	n/a	1	0	9.84
										2	5	,	

m: male, f: female, u: unilateral, b: bilateral, ri: right, le: left, t: primary tumor r: relapse,
r2: second relapse, ICRB: International Classification of Retinoblastoma, SE: secondary
a22
a23
a24
a24
ELISA, *: specimen after two cycles of melphalan, AH: aqueous humor, MRI: magnetic
resonance imaging, ¹: case identifiers used are not known to anyone outside the research
group and cannot reveal the identity of the study subjects

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

4. Discussion

In contrast to other cancer entities, molecular characterization of RB tumors mainly relays 329 on tumor samples derived from enucleations, as direct tumor biopsies bare the risk of 330 cancer cell seeding and spread outside the eye [49-51]. The identification of tumor bi-331 omarkers in RB liquid biopsies like aqueous humor and blood serum holds the potential 332 to improve diagnosis and therapy management of this childhood eye cancer without the 333 need for enucleation. Aqueous humor has been suggested as a surrogate for retinoblas-334 toma tissue [25,52]. It can safely be aspirated from retinoblastoma eyes and contains tu-335 mor-derived cfDNA, proteins and metabolic targets, but also potential biomarkers like 336 TFF1 [13,16,23,52–58]. Paracentesis of AH is minimally invasive and it is routinely aspi-337 rated from RB eyes undergoing salvage therapy with intravitreal injection of chemother-338 apeutics like melphalan. Nevertheless, this procedure entails the insertion of a fine-gauge 339 needle through the cornea, which carries a minimal risk of complications such as bleeding, 340 infection, cataract formation, iris trauma, and in theory, the potential for tumor cells to 341 spread to the orbit [59]. This raises the question if blood, a less invasive sample to obtain, 342 could also be a source for RB biomarkers like TFF1. 343

Our study presented aimed to explore the potential of TFF1 as a biomarker for retinoblas-344 toma in aqueous humor and blood serum of patients in general and under therapy. Mon-345 itoring liquid biopsies biomarker levels in RB diagnosis and under therapy may ultimately 346 enable a timely correlation between TFF1 expression levels in aqueous humor and/or 347 blood serum and RB progression. TFF1 has previously been identified as a functional bi-348 omarker in various other types of tumors, such as breast cancer [44,60], esophageal squa-349 mous cell carcinoma [61], and gastric cancer [62]. Notably, in breast cancer a correlation 350 between elevated TFF1 expression in blood samples of patients with compared to those 351 without metastatic disease was observed [42]. By evaluating TFF1 staining in tumor sec-352 tions post-enucleation, we and others already suggested TFF1 as a potential biomarker for 353 a specific subset of retinoblastomas [1,32]. We could initially demonstrate that TFF1 cor-354 relates with a higher clinical tumor-node-metastasis (TNM) stage and poorly differenti-355 ated tumor cells [32], later identified and specified as RB subtype 2 with a higher risk of 356 metastasis by Liu et al [1]. Most recently, we revealed for the first time that soluble TFF1 357 is secreted into the AH of RB patients [23]. 358

Here we analyzed AH of eight patients after enucleation as well as AH and corresponding blood serum of seven RB patients under therapy for TFF1 expression and secretion status. In addition, we investigated TFF1 expression in blood serum samples of control specimens including young children and adolescents in order to compare TFF1 levels of both groups. 363

The study presented verifies our previous findings [23] that TFF1 is secreted into the 364 AH of most patients analyzed after enucleation. All patients with TFF1 positive AH also 365 expressed TFF1 in the original tumor. Furthermore, we investigated if TFF1 is secreted 366 exclusively by RB tumor cells or also by tumor associated stromal cells. We therefore an-367 alyzed primary RB tumor cells and compared their endogenous TFF1 expression status 368 and ability to secrete TFF1 into the supernatant with RB tumor derived stromal cells. We 369 could show that only RB tumor cells and not RB derived stromal cells express and secrete 370 TFF1, rendering TFF1 a specific marker for RB tumor cells. 371

Analyzing AH of RB patients under therapy, we found three out of seven patients 372 initially secreting soluble TFF1 into the AH. Two of these patients completely lost TFF1 373 expression in their AH during IVC therapy with melphalan, indicating a direct influence 374 of the therapy regimen on TFF1 expression. The most obvious mechanistic explanation for 375 this loss could be the death of TFF1 expressing RB tumor cells during therapy suggesting 376 TFF1 a direct monitor for residual living tumor cells. In line with these results, one RB 377 tumor investigated displayed unvaried high TFF1 secretion into the AH during therapy 378 and developed a relapse after five month possibly indicating persisting RB tumor cells not 379 readily visible in funduscopy and sonography. One might hypothesize that particularly 380

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

tumors with a high stromal content respond well to therapy, but it may be mainly stromal381and not tumor cells which are susceptible to the treatment, a distinction that cannot be382made by funduscopy. In this case, TFF1 could be an extraordinary helpful marker for383monitoring residual RB tumor cells, still secreting this biomarker indicating the need for384higher frequent post-therapy screening of the respective RB patients.385

Furthermore, we investigated if TFF1 can also be detected in blood serum of RB pa-386 tients and if TFF1 levels might correlate with therapy efficacy. Some RB patients` blood 387 samples displayed detectable, yet very low concentrations of soluble TFF1, however with-388 out any correlation to TFF1 levels in the corresponding AH samples and with no correla-389 tion to the treatment outcome. Even in the control groups, only very low concentrations 390 of TFF1 were detectable. Thus, AH seems to be superior to blood serum as a liquid biopsy 391 for RB not only for detecting tumor-associated chromosomal changes in whole genome 392 sequencing [59], but also for TFF1 monitoring. Interestingly, however, no TFF1 expression 393 was detectable in non-RB children under the age of six in comparison to the older, adoles-394 cent control group (> 13 years), displaying low, but traceable levels. This may lead to the 395 assumption that healthy young children do not secrete TFF1 into the blood. 396

Summarizing one can state that the analysis of TFF1 in the AH of RB patients opens 397 the field for additional diagnostic approaches and therapy monitoring, using TFF1 as a 398 potential biomarker for RB tumor cells (Figure 6). 399

Nevertheless, it is necessary to further investigate TFF1 secretion into the AH during 400 therapy to develop a save future implementation of TFF1 in clinical diagnostic and treat-401 ment regimens. 402



403

Figure 6. Potential monitoring procedures of RB patients under treatment to improve the404outcome. Created with ©BioRender.com.405

- 407
- 408
- 409
- 410

	5. Conclusions	411			
	Analyzing liquid biopsies and identifying tumor biomarkers hold the potential to	412			
	improve the management of retinoblastoma therapy and provide clarity in clinically un-	413			
	vanced RB tumors and its expression correlates with a higher risk for metastases. We pro-	414			
	vided evidence for TFF1 therapy dependent expression changes in the AH of RB patients,	416			
	strongly suggesting TFF1 as a clinically interesting new RB biomarker in therapy moni-	417			
	toring.	418 419			
	Author Contributions: Conceptualization, MAB; methodology, AH and EA; validation, MAB and	420			
	AH; formal analysis, AH and EA; investigation, AH and EA; resources, EB and LJ; data curation, AH and MAB: writing—original draft preparation, MAB and ND: writing—review and editing	421 422			
	MAB and ND; visualization, MAB and AH; supervision, MAB and ND; project administration,	423			
	MAB and ND; All authors have read and agreed to the published version of the manuscript.	424			
	Funding: This research received no external funding.	425			
	Institutional Review Board Statement: The study was conducted according to the guidelines of the	426			
	Declaration of Helsinki, and approved by the Ethics Committee of the Medical Faculty of the Uni- versity of Duisburg Essen (approval # 06.30214; date of approval; 5/12/2006; approval # 14-5836 BO;	427 428			
	date of approval: 11/3/2020).	429			
	Informed Consent Statement: Informed consent was obtained from all subjects involved in the	430			
	study.	431			
	Acknowledgments: The authors would like to thank N. Bechrakis and T. Kiefer for their valuable support and A. Bollmeier for excellent technical assistance.	432 433			
	Conflicts of Interest: The authors declare no conflict of interest.	434			
Re	erences	435			
1					
1.	Liu, J.; Ottaviani, D.; Sefta, M.; Desbrousses, C.; Chapeaublanc, E.; Aschero, R.; Sirab, N.; Lubieniecki, F.; Lamas,	436			
	G.; Tonon, L.; et al. A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and	437			
0	neuronal/ganglion cell gene expression. <i>Nat. Commun.</i> 2021 , <i>12</i> , 5578, doi:10.1038/s41467-021-25792-0.	438			
2.	Singh, H.P.; Wang, S.; Stachelek, K.; Lee, S.; Reid, M.W.; Thornton, M.E.; Craft, C.M.; Grubbs, B.H.; Cobrinik, D.	439			
	Developmental stage-specific proliferation and retinoblastoma genesis in KB-deficient numan but not mouse	440			
C	cone precursors. Proc. Natl. Acad. Sci. U. S. A. 2018, 115, E9391-E9400, doi:10.10/3/pnas.1808903115.	441			
3.	Dimaras, H.; Corson, 1.W. Retinoblastoma, the visible CNS tumor: A review. J. Neurosci. Res. 2018,	442			
4	aor.10.1002/jiir.24215.	443			
4.	doi:10.1007/c00247.020.01081.v	444			
5	Roy S.R. Kaliki S. Rotinoblactoma: A. Major Roview, Mumercinal Med. J. 2021, 30, 881-895	445			
5. 6	Roy, J.R., Raiki, J. Reinoulasionia. A major Review. <i>Infymensingn Mea. J.</i> 2021 , 30, 881–893.				
0.	Dorsman IC Chantada G et al Retinoblastoma: From genes to patient care Fur I Med Const 2023 66				
	104674, doi:10.1016/i.eimg.2022.104674.				
7	Chronopoulos A Babst N Schiemenz C Schutz IS Heindl I M Ranibar M Kakkasserv V A Narrative	450			
	Review - Therapy Options and Therapy Failure in Retinoblastoma. <i>Neurosignals</i> . 2022 , 30, 39–58.	451			
	doi:10.33594/00000585.	452			

8.	Shields, C.L.; Bas, Z.; Laiton, A.; Silva, A.M.V.; Sheikh, A.; Lally, S.E.; Shields, J.A. Retinoblastoma: emerging concepts in genetics, global disease burden, chemotherapy outcomes, and psychological impact. <i>Eye (Lond)</i> 2023 , <i>37</i> ,	453 454
	815–822, doi:10.1038/s41433-022-01980-0.	455
9.	Kaewkhaw, R.; Rojanaporn, D. Retinoblastoma: Etiology, Modeling, and Treatment. Cancers (Basel) 2020, 12,	456
	doi:10.3390/cancers12082304.	457
10.	Munier, F.L.; Beck-Popovic, M.; Chantada, G.L.; Cobrinik, D.; Kivelä, T.T.; Lohmann, D.; Maeder, P.; Moll, A.C.;	458
	Carcaboso, A.M.; Moulin, A.; et al. Conservative management of retinoblastoma: Challenging orthodoxy without	459
	compromising the state of metastatic grace. "Alive, with good vision and no comorbidity". Prog. Retin. Eye Res.	460
	2019 , 73, 100764, doi:10.1016/j.preteyeres.2019.05.005.	461
11.	Temming, P.; Arendt, M.; Viehmann, A.; Eisele, L.; Le Guin, C.H.D.; Schündeln, M.M.; Biewald, E.; Astrahantseff,	462
	K.; Wieland, R.; Bornfeld, N.; et al. Incidence of second cancers after radiotherapy and systemic chemotherapy in	463
	heritable retinoblastoma survivors: A report from the German reference center. <i>Pediatr. Blood Cancer</i> 2017 , <i>64</i> , 71–	464
	80, doi:10.1002/pbc.26193.	465
12.	Campeau, E.; Ruhl, V.E.; Rodier, F.; Smith, C.L.; Rahmberg, B.L.; Fuss, J.O.; Campisi, J.; Yaswen, P.; Cooper, P.K.;	466
	Kaufman, P.D. A versatile viral system for expression and depletion of proteins in mammalian cells. <i>PLoS ONE</i>	467
4.0	2009 , <i>4</i> , e6529, doi:10.1371/journal.pone.0006529.	468
13.	Lawson, B.M.; Saktanasate, J.; Say, E.A.T.; Shields, C.L. Intravitreal chemotherapy provides control for massive	469
	vitreous seeding from retinoblastoma. Journal of pediatric ophthalmology and strabismus 2014, 51 Online, e92-4,	470
14	doi:10.3928/01913913-20141203-05.	471
14.	2015 62 141 145 doi:10.4102/0201.4728 154200	472
15	Erancis IH Abramson DH II X Shields CI Taivoira I E Schofler A C Cassoux N Hadiistilianou D	473
15.	Berry II · Frenkel S · et al Risk of Extraocular Extension in Eves With Retinoblastoma Receiving Intravitreous	474
	Chemotherapy IAMA Onhthalmal 2017 135 1426–1429 doi:10.1001/jamaonhthalmol.2017.4600	476
16.	Munier, F.L.: Gaillard, MC.: Balmer, A.: Beck-Popovic, M. Intravitreal chemotherapy for vitreous seeding in	477
10.	retinoblastoma: Recent advances and perspectives. Saudi I. Ophthalmol. 2013 , 27, 147–150.	478
	doi:10.1016/j.sjopt.2013.06.003.	479
17.	Shields, C.L.; Douglass, A.M.; Beggache, M.; Say, E.A.T.; Shields, J.A. INTRAVITREOUS CHEMOTHERAPY	480
	FOR ACTIVE VITREOUS SEEDING FROM RETINOBLASTOMA: Outcomes After 192 Consecutive Injections.	481
	The 2015 Howard Naquin Lecture. <i>Retina (Philadelphia, Pa)</i> 2016 , 36, 1184–1190,	482
	doi:10.1097/IAE.00000000000000003.	483
18.	Shields, C.L.; Lally, S.E.; Leahey, A.M.; Jabbour, P.M.; Caywood, E.H.; Schwendeman, R.; Shields, J.A. Targeted	484
	retinoblastoma management: when to use intravenous, intra-arterial, periocular, and intravitreal chemotherapy.	485
	Curr. Opin. Ophthalmol. 2014, 25, 374–385, doi:10.1097/ICU.0000000000000091.	486
19.	AlAli, A.; Kletke, S.; Gallie, B.; Lam, WC. Retinoblastoma for Pediatric Ophthalmologists. Asia Pac. J. Ophthal-	487
	mol. (Phila) 2018, 7, 160–168, doi:10.22608/APO.201870.	488
20.	Soliman, S.E.; Racher, H.; Zhang, C.; MacDonald, H.; Gallie, B.L. Genetics and Molecular Diagnostics in Reti-	489
	noblastomaAn Update. Asia Pac. J. Ophthalmol. (Phila) 2017, 6, 197–207, doi:10.22608/APO.201711.	490
21.	Soliman, S.E.; Wan, M.J.; Heon, E.; Hazrati, LN.; Gallie, B. Retinoblastoma versus advanced Coats' disease: Is	491
	enucleation the answer? <i>Ophthalmic Genet</i> . 2017 , <i>38</i> , 291–293, doi:10.1080/13816810.2016.1199715.	492
22.	Ghiam, B.K.; Xu, L.; Berry, J.L. Aqueous Humor Markers in Retinoblastoma, a Review. Transl. Vis. Sci. Technol.	493
	2019 , <i>8</i> , 13, doi:10.1167/tvst.8.2.13.	494

23.	Busch, M.A.; Haase, A.; Miroschnikov, N.; Doege, A.; Biewald, E.; Bechrakis, N.E.; Beier, M.; Kanber, D.; Loh-	495
	mann, D.; Metz, K.; et al. TFF1 in Aqueous Humor-A Potential New Biomarker for Retinoblastoma. <i>Cancers (Ba-</i>	496
24	sel) 2022, 14, doi:10.3390/cancers14030677.	497
24.	Martel, A.; Ballilf, S.; Nanon-Esteve, S.; Gastaud, L.; Bertolotto, C.; Komeo, B.; Mograbi, B.; Lassalle, S.; Horman,	498
	12. doi:10.2200/comport/20112284	499
25	12, doi:10.5590/calice1512115264.	500
23.	A : Kubn P : et al. Potential of Aqueous Humor as a Surrogate Tumor Bionsy for Potinoblastoma. <i>IAMA Onkthal</i>	501
	<i>mol.</i> 2017 , <i>135</i> , 1221–1230, doi:10.1001/jamaophthalmol.2017.4097.	502 503
26.	Im, D.H.; Pike, S.; Reid, M.W.; Peng, CC.; Sirivolu, S.; Grossniklaus, H.E.; Hubbard, G.B.; Skalet, A.H.;	504
	Bellsmith, K.N.; Shields, C.L.; et al. A Multicenter Analysis of Nucleic Acid Quantification Using Aqueous Hu-	505
	mor Liquid Biopsy in Retinoblastoma: Implications for Clinical Testing. <i>Ophthalmol. Sci.</i> 2023 , 3, 100289,	506
	doi:10.1016/j.xops.2023.100289.	507
27.	Ghose, N.; Kaliki, S. Liquid biopsy in Retinoblastoma: A review. <i>Semin. Ophthalmol.</i> 2022 , 37, 813–819,	508
	doi:10.1080/08820538.2022.2078165.	509
28.	Zhang, Z.; Wu, H.; Chong, W.; Shang, L.; Jing, C.; Li, L. Liquid biopsy in gastric cancer: predictive and prognostic	510
	biomarkers. Cell Death Dis. 2022, 13, 903, doi:10.1038/s41419-022-05350-2.	511
29.	Hou, Y.; Peng, Y.; Li, Z. Update on prognostic and predictive biomarkers of breast cancer. Semin. Diagn. Pathol.	512
	2022 , 39, 322–332, doi:10.1053/j.semdp.2022.06.015.	513
30.	Freitas, Ana Julia Aguiar de; Causin, R.L.; Varuzza, M.B.; Calfa, S.; Hidalgo Filho, Cassio Murilo Trovo; Komoto,	514
	T.T.; Souza, C.d.P.; Marques, M.M.C. Liquid Biopsy as a Tool for the Diagnosis, Treatment, and Monitoring of	515
	Breast Cancer. Int. J. Mol. Sci. 2022, 23, doi:10.3390/ijms23179952.	516
31.	Galardi, A.; Stathopoulos, C.; Colletti, M.; Lavarello, C.; Russo, I.; Cozza, R.; Romanzo, A.; Carcaboso, A.M.;	517
	Locatelli, F.; Petretto, A.; et al. Proteomics of Aqueous Humor as a Source of Disease Biomarkers in Retinoblas-	518
	toma. Int. J. Mol. Sci. 2022, 23, doi:10.3390/ijms232113458.	519
32.	Busch, M.; Metz, K.; Beier, M.; Biewald, E.; Dünker, N. TREFOIL FACTOR FAMILY 1 EXPRESSION CORRE-	520
	LATES WITH CLINICAL OUTCOME IN PATIENTS WITH RETINOBLASTOMA. Retina (Philadelphia, Pa) 2017,	521
	doi:10.1097/IAE.00000000001881.	522
33.	Hoffmann, W. Trefoil factors TFF (trefoil factor family) peptide-triggered signals promoting mucosal restitution.	523
	<i>Cell. Mol. Life Sci.</i> 2005 , <i>62</i> , 2932–2938, doi:10.1007/s00018-005-5481-9.	524
34.	Hoffmann, W. Trefoil Factor Family (TFF) Peptides and Their Diverse Molecular Functions in Mucus Barrier Pro-	525
	tection and More: Changing the Paradigm. Int. J. Mol. Sci. 2020, 21, doi:10.3390/ijms21124535.	526
35.	Braga Emidio, N.; Brierley, S.M.; Schroeder, C.I.; Muttenthaler, M. Structure, Function, and Therapeutic Potential	527
	of the Trefoil Factor Family in the Gastrointestinal Tract. ACS Pharmacol. Transl. Sci. 2020, 3, 583–597,	528
	doi:10.1021/acsptsci.0c00023.	529
36.	Heuer, J.; Heuer, F.; Stürmer, R.; Harder, S.; Schlüter, H.; Braga Emidio, N.; Muttenthaler, M.; Jechorek, D.;	530
	Meyer, F.; Hoffmann, W. The Tumor Suppressor TFF1 Occurs in Different Forms and Interacts with Multiple	531
	Partners in the Human Gastric Mucus Barrier: Indications for Diverse Protective Functions. Int. J. Mol. Sci. 2020,	532
	21, doi:10.3390/ijms21072508.	533
37.	Chu, G.; Qi, S.; Yang, G.; Dou, K.; Du, J.; Lu, Z. Gastrointestinal tract specific gene GDDR inhibits the progression	534
	ot gastric cancer in a TFF1 dependent manner. Mol. Cell. Biochem. 2012, 359, 369–374, doi:10.1007/s11010-011-1030-	535
	Ζ.	536

38.	Ge, Y.; Zhang, J.; Cao, J.; Wu, Q.; Sun, L.; Guo, L.; Wang, Z. TFF1 inhibits proliferation and induces apoptosis of	537
	gastric cancer cells in vitro. <i>Bosn. J. Basic Med. Sci.</i> 2012, 12, 74–81.	538
39.	Shi, Y.; Chen, GB.; Huang, QW.; Chen, X.; Liu, JJ.; Xu, W.; Huang, XX.; Liu, YP.; Xiao, CX.; Wu, DC.; et	539
	al. miR218-5p regulates the proliferation of gastric cancer cells by targeting TFF1 in an Erk1/2-dependent man-	540
	ner. Biochim. Biophys. Acta 2015, 1852, 970–979, doi:10.1016/j.bbadis.2015.01.016.	541
40.	Katsha, A.; Soutto, M.; Sehdev, V.; Peng, D.; Washington, M.K.; Piazuelo, M.B.; Tantawy, M.N.; Manning, H.C.;	542
	Lu, P.; Shyr, Y.; et al. Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric ne-	543
	oplasia. Gastroenterology 2013 , 145, 1312-22.e1-8, doi:10.1053/j.gastro.2013.08.050.	544
41.	Soutto, M.; Chen, Z.; Saleh, M.A.; Katsha, A.; Zhu, S.; Zaika, A.; Belkhiri, A.; El-Rifai, W. TFF1 activates p53	545
	through down-regulation of miR-504 in gastric cancer. Oncotarget 2014, 5, 5663–5673, doi:10.18632/oncotar-	546
	get.2156.	547
42.	Elnagdy, M.H.; Farouk, O.; Seleem, A.K.; Nada, H.A. TFF1 and TFF3 mRNAs Are Higher in Blood from Breast	548
	Cancer Patients with Metastatic Disease than Those without. J. Oncol. 2018, 2018, 4793498,	549
	doi:10.1155/2018/4793498.	550
43.	Ishibashi, Y.; Ohtsu, H.; Ikemura, M.; Kikuchi, Y.; Niwa, T.; Nishioka, K.; Uchida, Y.; Miura, H.; Aikou, S.; Gunji,	551
	T.; et al. Serum TFF1 and TFF3 but not TFF2 are higher in women with breast cancer than in women without	552
	breast cancer. <i>Sci. Rep.</i> 2017 , <i>7</i> , 4846, doi:10.1038/s41598-017-05129-y.	553
44.	Yi, J.; Ren, L.; Li, D.; Wu, J.; Li, W.; Du, G.; Wang, J. Trefoil factor 1 (TFF1) is a potential prognostic biomarker	554
	with functional significance in breast cancers. Biomed. Pharmacother. 2020, 124, 109827, doi:10.1016/j.bio-	555
	pha.2020.109827.	556
45.	Buache, E.; Etique, N.; Alpy, F.; Stoll, I.; Muckensturm, M.; Reina-San-Martin, B.; Chenard, M.P.; Tomasetto, C.;	557
	Rio, M.C. Deficiency in trefoil factor 1 (TFF1) increases tumorigenicity of human breast cancer cells and mam-	558
	mary tumor development in TFF1-knockout mice. Oncogene 2011, 30, 3261–3273, doi:10.1038/onc.2011.41.	559
46.	Weise, A.; Dünker, N. High trefoil factor 1 (TFF1) expression in human retinoblastoma cells correlates with low	560
	growth kinetics, increased cyclin-dependent kinase (CDK) inhibitor levels and a selective down-regulation of	561
	CDK6. Histochem. Cell Biol. 2013, 139, 323–338, doi:10.1007/s00418-012-1028-y.	562
47.	Philippeit, C.; Busch, M.; Dünker, N. Epigenetic control of trefoil factor family (TFF) peptide expression in hu-	563
	man retinoblastoma cell lines. Cell. Physiol. Biochem. 2014, 34, 1001–1014, doi:10.1159/000366316.	564
48.	Busch, M.; Grosse-Kreul, J.; Wirtz, J.J.; Beier, M.; Stephan, H.; Royer-Pokora, B.; Metz, K.; Dunker, N. Reduction	565
	of the tumorigenic potential of human retinoblastoma cell lines by TFF1 overexpression involves p53/caspase	566
	signaling and miR-18a regulation. Int. J. Cancer 2017, doi:10.1002/ijc.30768.	567
49.	Eide, N.; Walaas, L. Fine-needle aspiration biopsy and other biopsies in suspected intraocular malignant disease:	568
	a review. Acta Ophthalmologica 2009 , 87, 588–601, doi:10.1111/j.1755-3768.2009.01637.x.	569
50.	Karcioglu, Z.A. Fine needle aspiration biopsy (FNAB) for retinoblastoma. Retina (Philadelphia, Pa) 2002, 22, 707-	570
	710, doi:10.1097/00006982-200212000-00004.	571
51.	Ali, M.J.; Honavar, S.G.; Vemuganti, G.K.; Singh, A.D. Fine needle aspiration biopsy of retinal tumors. Mono-	572
	graphs in clinical cytology 2012 , 21, 72–81, doi:10.1159/000331038.	573
52.	Raval, V.; Racher, H.; Wrenn, J.; Singh, A.D. Aqueous humor as a surrogate biomarker for retinoblastoma tumor	574
	tissue. J. AAPOS 2022 , 26, 137.e1-137.e5, doi:10.1016/j.jaapos.2022.03.005.	575
53.	Smith, S.J.; Smith, B.D. Evaluating the risk of extraocular tumour spread following intravitreal injection therapy	576
	for retinoblastoma: A systematic review. Br. J. Ophthalmol. 2013, 97, 1231–1236, doi:10.1136/bjophthalmol-2013-	577
	303188.	578

54.	Ghassemi, F.; Shields, C.L.; Ghadimi, H.; Khodabandeh, A.; Roohipoor, R. Combined intravitreal melphalan and	579
	topotecan for refractory or recurrent vitreous seeding from retinoblastoma. JAMA Ophthalmol. 2014, 132, 936–941,	580
	doi:10.1001/jamaophthalmol.2014.414.	581
55.	Francis, J.H.; Schaiquevich, P.; Buitrago, E.; Del Sole, M.J.; Zapata, G.; Croxatto, J.O.; Marr, B.P.; Brodie, S.E.;	582
	Berra, A.; Chantada, G.L.; et al. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in reti-	583
	noblastoma: a preclinical and clinical study. <i>Ophthalmology</i> 2014 , <i>121</i> , 1810–1817, doi:10.1016/j.ophtha.2014.03.028.	584
56.	Smith, S.J.; Smith, B.D.; Mohney, B.G. Ocular side effects following intravitreal injection therapy for retinoblas-	585
	toma: A systematic review. Br. J. Ophthalmol. 2014, 98, 292–297, doi:10.1136/bjophthalmol-2013-303885.	586
57.	Uner, O.E.; Ulrich, B.C.; Hubbard, G.B. Potential of Aqueous Humor as a Surrogate Tumor Biopsy for Reti-	587
	noblastoma. JAMA Ophthalmol. 2018, 136, 597–598, doi:10.1001/jamaophthalmol.2018.0392.	588
58.	Liu, W.; Luo, Y.; Dai, J.; Yang, L.; Huang, L.; Wang, R.; Chen, W.; Huang, Y.; Sun, S.; Cao, J.; et al. Monitoring	589
	Retinoblastoma by Machine Learning of Aqueous Humor Metabolic Fingerprinting. Small Methods 2022, 6,	590
	e2101220, doi:10.1002/smtd.202101220.	591
59.	Berry, J.L.; Xu, L.; Polski, A.; Jubran, R.; Kuhn, P.; Kim, J.W.; Hicks, J. Aqueous Humor Is Superior to Blood as a	592
	Liquid Biopsy for Retinoblastoma. Ophthalmology 2020, 127, 552–554, doi:10.1016/j.ophtha.2019.10.026.	593
60.	Schulten, HJ.; Bangash, M.; Karim, S.; Dallol, A.; Hussein, D.; Merdad, A.; Al-Thoubaity, F.K.; Al-Maghrabi, J.;	594
	Jamal, A.; Al-Ghamdi, F.; et al. Comprehensive molecular biomarker identification in breast cancer brain metas-	595
	tases. J. Transl. Med. 2017, 15, 269, doi:10.1186/s12967-017-1370-x.	596
61.	Gonzaga, I.M.; Soares Lima, S.C.; Nicolau, M.C.; Nicolau-Neto, P.; da Costa, N.M.; Almeida Simão, T. de; Her-	597
	nandez-Vargas, H.; Herceg, Z.; Ribeiro Pinto, L.F. TFF1 hypermethylation and decreased expression in esopha-	598
	geal squamous cell carcinoma and histologically normal tumor surrounding esophageal cells. Clin. Epigenetics	599
	2017 , <i>9</i> , 130, doi:10.1186/s13148-017-0429-0.	600
62.	Shimura, T.; Dayde, D.; Wang, H.; Okuda, Y.; Iwasaki, H.; Ebi, M.; Kitagawa, M.; Yamada, T.; Yamada, T.;	601
	Hanash, S.M.; et al. Novel urinary protein biomarker panel for early diagnosis of gastric cancer. Br. J. Cancer	602
	2020 , <i>123</i> , 1656–1664, doi:10.1038/s41416-020-01063-5.	603
		604